Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 May;64(4):222-8.
doi: 10.1007/s00393-005-0732-6.

[Cardiovascular manifestations in rheumatoid arthritis]

[Article in German]
Affiliations
Review

[Cardiovascular manifestations in rheumatoid arthritis]

[Article in German]
F Moritz et al. Z Rheumatol. 2005 May.

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease, characterized by a polyarticular joint inflammation which eventually leads to joint destruction and general disability. Besides these polyarticular manifestations, several systemic immune phenomena have been described. An increased mortality in RA patients is evident and is mainly caused by an increased cardiovascular risk. The correlation between disease activity and mortality highlighted the important role of the systemic inflammatory reaction in induction and progression of vascular damaging processes. Endothelial dysfunction and vascular inflammation are important, mechanisms in atherosclerosis and induced by conventional risk factors and systemic inflammation. It has been shown that the deleterious influence of conventional risk factors is aggravated by inflammatory mediators, mainly by pro-inflammatory cytokines. In addition, certain inflammatory mediators exert damaging effects to blood vessels. Especially CRP, merely considered as a risk indicating parameter in the past, has attracted remarkable attention. Also certain RA specific immune phenomena are of considerable proatherosclerotic potential. At least in part, they could be responsible for the excess mortality in RA patients. The newer TNFalpha blocking agents interfere with different mechanisms responsible for induction and perpetuation of atherosclerotic processes. Time will show whether they make a remarkable impact on the cardiovascular mortality in RA patients.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Arthritis Rheum. 2001 Dec;44(12):2737-45 - PubMed
    1. Nature. 2000 Jan 13;403(6766):207-11 - PubMed
    1. J Biol Chem. 2004 Jan 9;279(2):963-9 - PubMed
    1. Curr Opin Rheumatol. 2002 Mar;14(2):115-20 - PubMed
    1. Lancet. 1997 Feb 15;349(9050):462-6 - PubMed

LinkOut - more resources